Literature DB >> 15905070

In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region.

Angela McCahill1, Theresa McSorley, Elaine Huston, Elaine V Hill, Martin J Lynch, Irene Gall, Guy Keryer, Birgitte Lygren, Kjetil Tasken, Gino van Heeke, Miles D Houslay.   

Abstract

We employ a novel, dominant negative approach to identify a key role for certain tethered cyclic AMP specific phosphodiesterase-4 (PDE4) isoforms in regulating cyclic AMP dependent protein kinase A (PKA) sub-populations in resting COS1 cells. A fraction of PKA is clearly active in resting COS1 cells and this activity increases when cells are treated with the selective PDE4 inhibitor, rolipram. Point mutation of a critical, conserved aspartate residue in the catalytic site of long PDE4A4, PDE4B1, PDE4C2 and PDE4D3 isoforms renders them catalytically inactive. Overexpressed in resting COS1 cells, catalytically inactive forms of PDE4C2 and PDE4D3, but not PDE4A4 and PDE4B1, are constitutively PKA phosphorylated while overexpressed active versions of all these isoforms are not. Inactive and active versions of all these isoforms are PKA phosphorylated in cells where protein kinase A is maximally activated with forskolin and IBMX. By contrast, rolipram challenge of COS1 cells selectively triggers the PKA phosphorylation of recombinant, active PDE4D3 and PDE4C2 but not recombinant, active PDE4A4 and PDE4B1. Purified, recombinant PDE4D3 and PDE4A4 show a similar dose-dependency for in vitro phosphorylation by PKA. Disruption of the tethering of PKA type-II to PKA anchor proteins (AKAPs), achieved using the peptide Ht31, prevents inactive forms of PDE4C2 and PDE4D3 being constitutively PKA phosphorylated in resting cells as does siRNA-mediated knockdown of PKA-RII, but not PKA-RI. PDE4C2 and PDE4D3 co-immunoprecipitate from COS1 cell lysates with 250 kDa and 450 kDa AKAPs that tether PKA type-II and not PKA type-I. PKA type-II co-localises with AKAP450 in the centrosomal region of COS1 cells. The perinuclear distribution of recombinant, inactive PDE4D3, but not inactive PDE4A4, overlaps with AKAP450 and PKA type-II. The distribution of PKA phosphorylated inactive PDE4D3 also overlaps with that of AKAP450 in the centrosomal region of COS1 cells. We propose that a novel role for PDE4D3 and PDE4C2 is to gate the activation of AKAP450-tethered PKA type-II localised in the perinuclear region under conditions of basal cAMP generation in resting cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905070     DOI: 10.1016/j.cellsig.2005.04.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  38 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3.

Authors:  Cecile Terrenoire; Miles D Houslay; George S Baillie; Robert S Kass
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

4.  Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.

Authors:  Xiang Li; George S Baillie; Miles D Houslay
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

Review 5.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

6.  A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells.

Authors:  Lindsay S Wilson; George S Baillie; Lisa M Pritchard; Bibiana Umana; Anna Terrin; Manuela Zaccolo; Miles D Houslay; Donald H Maurice
Journal:  J Biol Chem       Date:  2011-03-10       Impact factor: 5.157

7.  PDE8A runs interference to limit PKA inhibition of Raf-1.

Authors:  Donald H Maurice
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

8.  Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Authors:  Lan Xiao; James P O'Callaghan; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

9.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

10.  Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.

Authors:  George S Baillie; David R Adams; Narinder Bhari; Thomas M Houslay; Suryakiran Vadrevu; Dong Meng; Xiang Li; Allan Dunlop; Graeme Milligan; Graeme B Bolger; Enno Klussmann; Miles D Houslay
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.